- Home
- BR vs ILMN Comparison
BR vs ILMN Comparison
Compare BR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BR
- ILMN
- Stock Information
- Founded
- BR 1962
- ILMN 1998
- Country
- BR United States
- ILMN United States
- Employees
- BR N/A
- ILMN N/A
- Industry
- BR Business Services
- ILMN Medical Specialities
- Sector
- BR Consumer Discretionary
- ILMN Health Care
- Exchange
- BR Nasdaq
- ILMN Nasdaq
- Market Cap
- BR 27.6B
- ILMN 23.6B
- IPO Year
- BR 2007
- ILMN 2000
- Fundamental
- Price
- BR $224.28
- ILMN $135.07
- Analyst Decision
- BR Hold
- ILMN Buy
- Analyst Count
- BR 8
- ILMN 19
- Target Price
- BR $226.71
- ILMN $162.67
- AVG Volume (30 Days)
- BR 515.0K
- ILMN 2.4M
- Earning Date
- BR 01-30-2025
- ILMN 02-06-2025
- Dividend Yield
- BR 1.56%
- ILMN N/A
- EPS Growth
- BR 2.64
- ILMN N/A
- EPS
- BR 5.79
- ILMN N/A
- Revenue
- BR $6,498,600,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- BR $9.50
- ILMN N/A
- Revenue Next Year
- BR $5.42
- ILMN $4.05
- P/E Ratio
- BR $39.05
- ILMN N/A
- Revenue Growth
- BR 4.67
- ILMN N/A
- 52 Week Low
- BR $188.30
- ILMN $97.36
- 52 Week High
- BR $237.96
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- BR 40.74
- ILMN 41.54
- Support Level
- BR $222.57
- ILMN $130.31
- Resistance Level
- BR $228.09
- ILMN $137.69
- Average True Range (ATR)
- BR 3.80
- ILMN 5.34
- MACD
- BR -1.79
- ILMN -1.07
- Stochastic Oscillator
- BR 10.85
- ILMN 27.38
About BR Broadridge Financial Solutions Inc.
Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communications and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two segments: investor communication solutions and global technology and operations.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.